M.D. Anderson Cancer Center
mdanderson.orgTotal trials
2,998
Active
1,060
Phase 3
134
Total enrollment
802,591
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 527 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Nicotine Patch | — | — | 11 | ||||
| Varenicline | — | — | — | 6 | |||
| Nicotine Replacement | — | — | — | — | 4 | ||
| Hydromorphone | — | — | — | — | 2 | ||
| Bupropion Hydrochloride Controlled-release | — | — | — | — | — | 1 | |
| Recombinant Human Papillomavirus Nonavalent Vaccine | — | — | — | — | — | 1 | |
| Methylnaltrexone | — | — | — | — | — | 1 | |
| PCV20 | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | 69 | |||
| Nivolumab | — | — | 66 | ||||
| Dexamethasone | — | 84 | |||||
| Fludarabine Phosphate | — | — | 42 | ||||
| Ipilimumab | — | — | 48 | ||||
| Cisplatin | — | — | 55 | ||||
| Cladribine | — | — | — | 16 | |||
| Busulfan | — | — | 53 | ||||
| Chemotherapy | — | — | 11 | ||||
| Apalutamide | — | — | — | — | 8 | ||
| Thiotepa | — | — | — | 14 | |||
| Methylphenidate | — | — | — | 8 | |||
| Radiation Therapy | — | — | — | 4 | |||
| Etoposide | — | — | — | 40 | |||
| Liposomal Bupivacaine | — | — | — | — | 5 | ||
| Haloperidol | — | — | — | — | — | 3 | |
| Chlorpromazine | — | — | — | — | — | 2 | |
| Anamorelin Hydrochloride | — | — | — | — | 2 | ||
| Lorazepam | — | — | — | — | 2 | ||
| Tranexamic Acid | — | — | — | — | 2 | ||
| Morphine | — | — | 5 | ||||
| Bupivacaine | — | — | — | — | 3 | ||
| Fentanyl | — | — | — | 4 | |||
| Hydromorphone Hydrochloride | — | — | — | — | 2 | ||
| Mitotane | — | — | — | — | 2 | ||
| Valproate | — | — | — | — | 2 | ||
| Telotristat Ethyl | — | — | — | — | 2 | ||
| Open Label Placebo | — | — | — | — | — | 1 | |
| Fentanyl Citrate Buccal | — | — | — | — | — | 1 | |
| Androgen Deprivation Therapy | — | — | — | — | — | 1 | |
| Fluorouracil 5-FU | — | — | — | — | — | 1 | |
| Fluorouracil/Calcipotriene | — | — | — | — | — | 1 |
487 more active programs hidden
Next readouts
- 2016-05-15
- 2016-08-26
- 2017-05-24
- 2017-12-30
- 2019-03-28
- 2019-12-27
- 2021-02-28
- 2021-02-28
- 2021-05-05
- 2021-06-05
Top conditions
- Leukemia206
- Breast Cancer141
- Lymphoma136
- Lung Cancer94
- Prostate Cancer82
- Myelodysplastic Syndrome79
- Advanced Cancers69
- Acute Myeloid Leukemia67
Frequently asked questions about M.D. Anderson Cancer Center
- How many clinical trials does M.D. Anderson Cancer Center have on ClinicalTrials.gov?
- M.D. Anderson Cancer Center is listed as the lead sponsor on 2,998 clinical trials in ClinicalTrials.gov, 1,060 of which are currently active (recruiting, enrolling, or ongoing).
- How many of M.D. Anderson Cancer Center's trials are in Phase 3?
- 134 of M.D. Anderson Cancer Center's trials are in Phase 3, spread across 527 active drug programs.
- What therapeutic areas does M.D. Anderson Cancer Center focus on?
- M.D. Anderson Cancer Center's most-studied conditions on ClinicalTrials.gov are Leukemia, Breast Cancer, Lymphoma, Lung Cancer, Prostate Cancer.
- When are M.D. Anderson Cancer Center's next clinical trial readouts?
- M.D. Anderson Cancer Center has 10 upcoming primary-completion readouts tracked here; the soonest is “The Effects of Ginseng on Cancer-Related Fatigue”, expected around 2016-05-15.